Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Crunchfish Digital Cash non-mobile devices webinar

Crunchfish's contribution to the global hackathon RBI Harbinger was presented at the 21st Survival of the fittest webinar. Crunchfish’s solution enables cards and wearables to have contactless interaction with mobiles. This is important for financial inclusion as non-mobile devices interact with stored values on mobiles, even in an offline mode.Crunchfish Digital Cash is an extremely versatile platform, able to support many use cases in digital payments. Most importantly, it delivers offline payments, which are key for enabling the projected explosive growth in digital payments. There are

Klaria Pharma to Present at BioStock Life Science Spring Summit 2022 on June 8th

UPPSALA, 3 June, 2022. Klaria Pharma AB (Nasdaq Stockholm: KLAR) announces today that the company‘s CEO, Jesper Wiklund, will participate at the BioStock Life Science Spring Summit 2022 on June 8[th] and present Klaria Pharma.  Klaria Pharma’s presentation will start at 14:00/2 pm CET. Follow the event online here: https://youtu.be/RmhNVEZSCww For additional information please contact: Investor Relations, Klaria Pharma ABTel: +46 (0)8 446 42 99, e-mail: investor.relations@klaria.com

Auditors’ Report Inzile Financial Year 2021 Published

Inzile AB (publ) has now published the English translation of the Auditor’s Report for financial year 2021, that was published in Swedish on May 31, 2022. For further information, please contact: Måns Sjöstedt, CEO Inzile, mans.sjostedt@inzile.com, +46 70 946 69 05 Peter Wergens, CFO Inzile, peter.wergens@inzile.com, +46 73 325 75 04 This information is such that Inzile AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation (MAR). The information was provided by the above contact persons, for publication on June 3, 2022 at 12.00 CET.

SBB successfully issues its first EUR social Schuldscheindarlehen

Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) has successfully closed its inaugural Schuldscheindarlehen (“SSD”) transaction that was placed with global fixed income investors. The social SSD was executed in two floating rate tranches with a maturity of three years and five years, respectively. The new SSD was priced with a spread to maturity of EURIBOR plus 145 bps and EURIBOR plus 170bps, respectively. This transaction marks a further step in SBB’s investor diversification journey and demonstrates strong continuous access to the global capital markets. Following the issuance, SBB

Patent approved in Europe

SpectraCure's patent application for a new technology, to improve the company's IDOSE® technology, has been approved by the European Patent Office, EPO. The IDOSE® technology is central to SpectraCure's method of treating prostate cancer with photodynamic tumor therapy (PDT). In short, IDOSE® technology means that the prostate tissue is monitored during treatment with a series of different measurements to ensure that the correct dose is given, so that the tumour is eliminated, without damaging healthy surrounding tissue. The new patent protects a method for detecting and compensating for

Observe Medical ASA – Minutes from Annual General Meeting

Observe Medical ASA has today, June 3, 2022, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com. For further information, please contact:  Rune Nystad, CEO Observe MedicalMobile: +47 916 24 683E-mail: rune.nystad@observemedical.com Per Arne Nygård, CFO of Observe MedicalMobile: +47 411 04 345E-mail: perarne.nygard@observemedical.com This information is subject of the disclosure

K2A winner of this year’s Symbiosis – an award for responsible business

The real estate company K2A Knaust & Andersson Fastigheter AB is one of the winners of Symbiosis – an award for Swedish companies that successfully combine responsible and profitable growth. In its motivation, the jury highlighted in particular K2A’s responsible profile in an ever-current industry.“We are very proud to receive this award and hope it will mean more people recognise the link between sustainability, a long-term approach and profitability – even in the real estate sector. For us, it is a matter of course that residential real estate companies of the future must be able to build

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 EULAR Congress

• Data suggest efficacy over standard of care for the treatment of psoriatic arthritis • Izokibep was well-tolerated, having a safety profile consistent with previous studies and the IL-17A inhibitor therapeutic class • Supports hypothesis that izokibep offers greater efficacy with high potency and small size, as well as strategy of evaluating IL-17A inhibition’s potential for transformative efficacy across many disease states Solna, Sweden, Los Angeles, USA, and Shanghai, China, June 3, 2022 – ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals today announced data from a

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release June 3, 2022 at 12:15 p.m. Nokian Tyres has received an announcement from JPMorgan Chase & Co. on June 2, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the indirect holding and total holding in Nokian Tyres shares owned by the funds and accounts managed by JPMorgan Chase & Co. fell below the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on June 1, 2022. The indirect shareholding of the funds and accounts managed by JPMorgan Chase

CS MEDICA A/S: CFO Gitte Lund Henriksen buys more shares in the Company

CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the CFO of the Company, Gitte Lund Henriksen, has today acquired 10 159 shares in CS MEDICA at a price of 5,88, amounting to a total value of 59 824,52 DKK including commission.CFO and board member of CS MEDICA, Gitte Lund Henriksen, has purchased 10 159 shares in the open market at a price of DKK 5,88 per share, corresponding to a total purchase of 59 824,52 DKK including commission. The transaction has been disclosed in the Danish financial supervisory register. Following the transaction, Gitte Lund Henriksen owns 4 037 000

Pricer to showcase next generation solutions to drive forward in-store capabilities at Shoptalk Europe

Pricer, the leading in-store communications company and market-leader in the provision of Electronic Shelf Label (ESL) solutions, will be showcasing its latest technologies that improve in-store operational performance and elevate customer experience (CX) at Shoptalk Europe (06 – 08 June, Excel London).From bringing digital engagement to life at the shelf edge, to driving efficiencies in store operations and enabling dynamic pricing capabilities to increase conversions, maintain margin and realize sustainability targets, each application of Pricer’s ESL solutions is designed to fast-track

Speqta determines record date for reverse share split

At the annual general meeting of Speqta AB (publ), reg. no. 556710-8757 (“Speqta”) on 25 May 2022 a reverse share split of Speqtas shares was resolved upon, whereby ten (10) existing shares will be consolidated into one (1) share. The meeting authorized the board of directors to determine the record date for the reverse share split. The board of directors of Speqta has today, by virtue of the authorization, resolved that the record date for the reverse share split shall be 10 June 2022.  Timetable for the reverse share split:8 June 2022Last day of trading before the reverse

LKAB and Salzgitter Group forge technical cooperation agreement

The Swedish mining group LKAB and Salzgitter AG have agreed to cooperate on the decarbonizationof the steel industry and have therefore forged a technical cooperation agreement. Both sidesperceive the agreement as an important step for the expansion and further development of the decadeslongpartnership.According to the SALCOS® - Salzgitter Low CO2 Steelmaking program, the Salzgitter Group will have incrementally realized virtually CO2-free steel production by 2033, subject to expedient and suitable economic policy framework conditions and significant public subsidies. LKAB produces

Neste signs a green term loan agreement

Neste Corporation, Press Release, 3 June 2022 at 11:45 a.m. (EET) Neste has signed today a EUR 500 million green term loan agreement. The proceeds of the loan will be used to finance Eligible Assets and Projects in accordance with Neste’s Green Finance Framework. The loan has a tenor of 3 years with two 1-year extension options. Danske Bank A/S and OP Corporate Bank plc acted as coordinating mandated lead arrangers and bookrunners of the loan.  Neste established the Green Finance Framework in 2021 to further integrate the company’s sustainability ambitions into its financing. The

SkartaNYAB Plc establishes new share-based incentive plans

SkartaNYAB PlcCOMPANY ANNOUNCEMENT03 June 2022 at 11:45SkartaNYAB Plc establishes new share-based incentive plans The Board of Directors of SkartaNYAB Plc has decided to establish new share-based incentive plans for the employees and executives of SkartaNYAB Group. The plans include a performance share plan, a project bonus share plan, as well as a share issue directed to the personnel. The objective of the plans is to align the interests of the employees and SkartaNYAB shareholders by strengthening the long-term ownership of employees and executives and, thus, to increase the

Addtech acquires Arruti Group

Addtech Energy a business area in the Addtech Group, has today signed an agreement to acquire 100 % of the shares outstanding in Arruti Group (“Arruti”) Arruti Group consists of four companies that develop, manufacture and sell components as well as equipment components for electrical transmission lines and substations. The company is well established as a supplier to grid operators in Europe, parts of South America and Canada. Arruti Group is headquartered in Bilbao, Spain, has 90 employees and annual sales of approximately EUR 27 million. Arruti Group complements very well the

Enviro Launches new website

Enviro has launched a new website as part of the company’s updated graphic profile and brand platform. The new website is an important tool and representation of Enviro developing from a promising Swedish technology company to a global, commercial player.“The website is our most important channel to communicate with our shareholders, potential clients and people that are interested in our work. We have involved a large section of our employees and the board of directors in the work to update our graphic profile, brand platform, and website, and are proud of what we have been able to achieve

XMReality receives order from a Japanese car manufacturer through the partnership with NTT

The Thai unit of a large Japanese car manufacturer has placed an order for XMReality Remote Guidance through NTT. XMReality has a partnership agreement in place with NTT (Nippon Telegraph and Telephone) since October 2020 so that NTT can market and sell XMReality Remote Guidance[TM].The car manufacturer has placed the order directly with NTT, who then orders the service from XMReality. This is the first order generated by this partnership. “I’m very pleased to see that this partnership with NTT is starting to yield revenue for XMReality”, says Andreas Jonsson, CSO at XMReality. “Going

BNP Paribas strengthens its position in the Nordic region with another senior hire

Michael Zeier joins BNP Paribas as a senior investment banker for the Nordic region. In addition to advising clients across sectors, Michael will be responsible for the activities of the Low Carbon Transition Group in the Nordics. “We are very pleased to welcome Michael to BNP Paribas and I am very excited about having such an experienced investment banker on our platform”, says Eirik Winter, CEO for BNP Paribas Group Nordic regionMichael has extensive experience of working with Nordic clients on corporate finance transactions. He was previously responsible for Nordic Investment banking at

Development of Fellow Bank's loan and deposit portfolio in May

FELLOW BANK PLC PRESS RELEASE 3.6.2022 AT 11:00 AM EESTFellow Bank has had a strong start. In May 2022, Fellow Bank provided funding worth of EUR 26.1 million. The loan portfolio totaled EUR 96.6 million at the end of the month. Deposits totaled EUR 226.2 million at the end of the month. Fellow Bank, which invests in easy-to-use digital service channels, currently offers flexible financial services for SMEs and personal customers, as well as a competitive and secure return on deposits with savings accounts and time deposits. The service offering will expand gradually during 2022.

BioStock: Elicera receives funding for clinical trials with ELC-301

Gene therapy company Elicera Therapeutics has been awarded 2.5 million Euros in funding from the European Innovation Council (EIC) Accelerator Programme. The grant is great news for the company, which now has sufficient funds to conduct Elicera's planned clinical phase I/II study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma.Read the full article at biostock.se: https://www.biostock.se/en/2022/06/elicera-erhaller-finansiering-for-kliniska-studier-med-elc-301/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Abliva secures funding to advance KL1333 into phase II/III

It has undeniably been an eventful week for Swedish biotech Abliva. On Tuesday, the company, whose focus is primary mitochondrial diseases, announced that they are conducting a 200 MSEK financing round. The bulk of the raised capital will be used to finance the upcoming registrational phase II/III trial with lead candidate KL1333.Read the full article at biostock.se: https://www.biostock.se/en/2022/06/abliva-secures-funding-to-advance-kl1333-into-phase-ii-iii/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

DEVERSIFY SELECTED FOR EIT HEALTH’S BRIDGEHEAD PROGRAMME 2022

Deversify AB is a Swedish health tech company offering solutions for improved individual health and wellbeing. The company has been handpicked as one of 29 start-ups and scale-ups to participate in the prestigious Bridgehead Programme. Bridgehead serves to support promising health companies in gaining crucial connections and experience through EIT Health’s vast and diverse network. ”Bridgehead is a dream opportunity for us to build presence in more European countries and ultimately, through this impressive network, to improve health beyond any borders. We are particularly proud to

Photocure ASA: Exercise of employee share options

Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 June 2022 regarding exercise of share options.The price for option shares sold by the primary insiders, has been determined at a price of NOK 102.072 per share. The primary insiders having exercised options has used the net proceeds from the sale of option shares to purchase shares in Photocure at a price per share of NOK 102.072 as follows: · Dan Schneider, President and CEO, has purchased 29,435 shares · Erik Dahl, CFO, has purchased 5,887

There are no items matching the current filter
There are no more items matching the current filter
Back to top